Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Y. [1 ]
Zuo, J. [1 ]
Feng, L. [1 ]
Fan, Z. [1 ]
Wang, L. [1 ]
Zhang, X. [1 ]
Han, J. [1 ]
Zhou, X. [1 ]
Ye, J. [2 ]
Li, B. [2 ]
Lizaso, A. [2 ]
Zhou, J. [2 ]
机构：
[1] Hebei Med Univ, Hosp 4, Med Oncol, Shijiazhuang, Hebei, Peoples R China
[2] Burning Rock Biotech, Med, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1431
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1229P
引用
收藏
页码：S799 / S800
页数：2
相关论文
共 50 条
  • [31] LACE-BIO POOLED ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF TP53 MUTATIONS IN COMPLETELY RESECTED NON SMALL CELL LUNG CANCER (NSCLC)
    Hainaut, P.
    Ma, X.
    Lacas, B.
    Tsao, M.
    Douillard, J.
    Rousseau, V.
    Dunant, A.
    Seymour, L.
    Filipits, M.
    Graziano, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 389 - 389
  • [32] Profiling the Metastatic Potential of Non-Small Cell Lung Cancer Patients Based on TP53 Classification
    Lu, J.
    Lou, Y.
    Zhong, R.
    Sun, J.
    Zhong, H.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S513 - S513
  • [33] Frequency of TP53 mutations in relation to Arg72Pro genotypes in non-small cell lung cancer
    Lind, Helge
    Ekstrom, Per Olaf
    Ryberg, David
    Skaug, Vidar
    Andreassen, Tove
    Stangeland, Lodve
    Haugen, Aage
    Zienolddiny, Shanbeh
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (10) : 2077 - 2081
  • [34] TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis
    deAnta, JM
    Jassem, E
    Rosell, R
    MartinezRoca, M
    Jassem, J
    MartinezLopez, E
    Monzo, M
    SanchezHernandez, JJ
    Moreno, I
    SanchezCespedes, M
    ONCOGENE, 1997, 15 (24) : 2951 - 2958
  • [35] TP53 mutations reprogram fatty acid metabolism and tumor microenvironment in African American patients with non-small cell lung cancer
    Liu, Liang
    Mehraein-Ghomi, Farideh
    Forbes, Elizabeth
    Topaloglu, Umit
    Petty, W. Jeffrey
    Grant, Stefan
    Ruiz, Jimmy
    Foley, Kristie L.
    Winkfield, Karen
    Pasche, Boris
    Zhang, Wei
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [36] TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis
    Josep Maria de Anta
    Ewa Jassem
    Rafael Rosell
    Marta Martínez-Roca
    Jacek Jassem
    Eva Martínez-López
    Mariano Monzó
    José Javier Sánchez-Hernández
    Isabel Moreno
    Montserrat Sánchez-Céspedes
    Oncogene, 1997, 15 : 2951 - 2958
  • [37] VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
    Schwaederle, Maria
    Lazar, Vladimir
    Validire, Pierre
    Hansson, Johan
    Lacroix, Ludovic
    Soria, Jean-Charles
    Pawitan, Yudi
    Kurzrock, Razelle
    CANCER RESEARCH, 2015, 75 (07) : 1187 - 1190
  • [38] TP53 Mutations in Nonsmall Cell Lung Cancer
    Mogi, Akira
    Kuwano, Hiroyuki
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [39] Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
    Kim, Seung Tae
    Sung, Jae Sook
    Jo, Uk Hyun
    Park, Kyong Hwa
    Shin, Sang Won
    Kim, Yeul Hong
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [40] Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
    Seung Tae Kim
    Jae Sook Sung
    Uk Hyun Jo
    Kyong Hwa Park
    Sang Won Shin
    Yeul Hong Kim
    Medical Oncology, 2013, 30
12345